当前位置: 首页 » 政策法规 » 国外法规 »欧盟拒绝DHA有助于提高记忆功能等声称

欧盟拒绝DHA有助于提高记忆功能等声称

扫描二维码 分享好友和朋友圈
放大字体  缩小字体 2017-07-07 08:09:18  来源:欧盟委员会  浏览次数:5065
核心提示:2017年7月5日,欧盟发布(EU) 2017/1200法规,拒绝DHA、聚葡萄糖、Fabenol® Max的相关声称。欧盟拒绝授权DHA有助于提高记忆功能,聚葡萄糖能够改善肠道功能,Fabenol® Max降低碳水化合物的吸收功能的健康声称。
发布单位
欧盟委员会
欧盟委员会
发布文号 (EU) 2017/1200
发布日期 2017-07-05 生效日期 2017-07-26
有效性状态 废止日期 暂无
备注 2017年7月5日,欧盟发布(EU) 2017/1200法规,拒绝DHA、聚葡萄糖、Fabenol® Max的相关声称。欧盟拒绝授权DHA有助于提高记忆功能,聚葡萄糖能够改善肠道功能,Fabenol® Max降低碳水化合物的吸收功能的健康声称。

COMMISSION REGULATION (EU) 2017/1200 of 5 July 2017

refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods (1), and in particular Article 18(5) thereof,

Whereas:

(1)

Pursuant to Regulation (EC) No 1924/2006 health claims made on foods, as defined in that Regulation, are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.

(2)

Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State. The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as ‘the Authority’, for a scientific assessment, as well as to the Commission and the Member States for information.

(3)

The Authority is to deliver an opinion on the health claim concerned.

(4)

The Commission is to decide on the authorisation of health claims taking into account the opinion delivered by the Authority.

(5)

Following an application from Ecopharma BVBA, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Fabenol® Max, a standardised aqueous extract from Phaseolus vulgaris L., and the reduction of the absorption of carbohydrates (Question No EFSA-Q-2015-00123 (2)). The claim proposed by the applicant was worded as follows: ‘Fabenol® Max reduces the absorption of carbohydrates’.

(6)

On 23 February 2016, the Commission and the Member States received the scientific opinion from the Authority, which noted that the claimed effect was not sufficiently defined and that the applicant did not provide any further information as requested by the Authority. Therefore, on the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the consumption of Fabenol® Max and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

(7)

Following an application from DSM Nutritional Products, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to docosahexaenoic acid (DHA) and improvement of memory function (Question No EFSA-Q-2015-00456 (3)). The claim proposed by the applicant was worded as follows: ‘DHA contributes to improved memory function’.

(8)

On 2 May 2016, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of DHA and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

(9)

Following an application from Tate & Lyle PLC, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to polydextrose and normal defecation (Question No EFSA-Q-2015-00550 (4)). The claim proposed by the applicant was worded as follows: ‘Polydextrose contributes to an improved bowel function by increasing stool bulk’.

(10)

On 25 May 2016, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of polydextrose and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

(11)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

HAS ADOPTED THIS REGULATION:

Article 1

The health claims listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 5 July 2017.

For the Commission

The President

Jean-Claude JUNCKER


(1)  OJ L 404, 30.12.2006, p. 9.

(2)  EFSA Journal 2016;14(2):4401.

(3)  EFSA Journal 2016;14(5):4455.

(4)  EFSA Journal 2016;14(5):4480.


ANNEX

Rejected health claims

Application — Relevant provisions of Regulation (EC) No 1924/2006

Nutrient, substance, food or food category

Claim

EFSA opinion reference

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data

Fabenol® Max

Fabenol® Max reduces the absorption of carbohydrates

Q-2015-00123

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data

DHA

DHA contributes to improved memory function

Q-2015-00456

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data

Polydextrose

Polydextrose contributes to an improved bowel function by increasing stool bulk

Q-2015-00550

食品伙伴网提供标准法规解读、舆情监控、合规咨询、申报注册等服务。
电询:0535-2129301
QQ:2891238009
食品标法圈
实时把握食品标法动态
请扫码关注食品标法圈

声明:

① 凡本网所有原始/编译文章及图片、图表的版权均属食品伙伴网所有,如要转载,需注明“信息来源:食品伙伴网”。
② 凡本网注明“信息来源:XXX(非食品伙伴网)”的作品,均转载自其他媒体,转载目的在于传递更多的信息,并不代表本网赞同其观点和对其真实性负责。
※ 邮箱:law#foodmate.net(发邮件时请将#换成@) QQ:139307733

 
 
[ 政策法规搜索 ]  [ 加入收藏 ]  [ 告诉好友 ]  [ 打印本文 ]  [ 关闭窗口 ]

 

 
 
按分类浏览
国家法规 (11359) 国外法规 (3603)
地方法规 (39770) 法规动态 (191)
法规解读 (2623) 其他法规 (506)
推荐国外法规
点击排行
按国家或地区浏览

法规中心  关于我们  广告业务  联系我们  信息服务

Processed in 0.267 second(s), 10 queries, Memory 4.5 M